FIELD: medicine, oncology, biochemistry, pharmacy.
SUBSTANCE: invention relates to a medicinal agent used in treatment of prostate cancer containing compound of the formula (I): 
or its pharmaceutically acceptable salt, and to a pharmaceutical composition containing the indicated compound. Also, invention relates to a method for treatment of prostate cancer suggesting administration of such compound and to using this compound in treatment of prostate cancer. Invention provides expanding assortment of drugs used in treatment of prostate cancer.
EFFECT: valuable medicinal properties of drug.
7 cl, 2 tbl, 5 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS OF SPECIFIC CLASS I HISTONE DEACETYLASE INHIBITORS AND PROTEASOME INHIBITORS | 2007 |
|
RU2456990C2 |
| COMBINATIONS | 2015 |
|
RU2715236C2 |
| APPLICATION OF IMIDAZOQUINOLINES FOR TREATMENT OF EGFR-DEPENDENT DISEASES OR DISEASES WITH AQUIRED RESISTANCE TO AGENTS BINDING MEMBERS OF EGFR FAMILY | 2008 |
|
RU2481838C2 |
| PHOSPHODIESTERASE 9A AS MARKER OF MALIGNANT TUMOR OF PROSTATE GLAND | 2010 |
|
RU2592668C2 |
| COMBINATION OF INHIBITOR FGFR AND INHIBITOR IGF1R | 2015 |
|
RU2715893C2 |
| COMBINED DRUG FOR TREATMENT OF TUMOR DISEASES | 2002 |
|
RU2291710C2 |
| APPLICATION OF ANTICANCER TRANSCRIPT MODIFYING AGENTS AND CHEMOTHERAPY OR RADIOTHERAPY | 2005 |
|
RU2389484C2 |
| METHOD OF TREATING CANCER (VERSIONS) | 2006 |
|
RU2447889C2 |
| COMBINED THERAPY WITH EZH2 INHIBITOR | 2018 |
|
RU2754131C1 |
| METHODS OF TREATING CANCER DISEASES AND TUMORS USING PDE1 INHIBITORS | 2019 |
|
RU2811918C2 |
